Capstone Therapeutics

OverviewSuggest Edit

Capstone Therapeutics is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
TypePublic
Founded1987
HQTempe, US
Websitecapstonethx.com

Locations

Capstone Therapeutics is headquartered in
Tempe, United States

Location Map

Latest Updates

Employees (est.) (Apr 2017)9
Revenue (FY, 2018)($2 M)
Share Price (Oct 2020)$15
Cybersecurity ratingAMore

Key People/Management at Capstone Therapeutics

Elwood D. Howse

Elwood D. Howse

Director
Michael M. Toporek

Michael M. Toporek

Director
Matthew E. Lipman

Matthew E. Lipman

Director
John M. Holliman

John M. Holliman

Chairman & CEO
Show more

Capstone Therapeutics Office Locations

Capstone Therapeutics has an office in Tempe
Tempe, US (HQ)
1275 W Washington St
Show all (1)

Capstone Therapeutics Financials and Metrics

Capstone Therapeutics Revenue

Capstone Therapeutics's revenue was reported to be ($2 m) in FY, 2018
USD

Net income (Q2, 2019)

(668.0k)

EBIT (Q2, 2019)

(605.0k)

Market capitalization (16-Oct-2020)

815.7k

Closing stock price (16-Oct-2020)

15.0

Cash (30-Jun-2019)

305.0k
Capstone Therapeutics's current market capitalization is $815.7 k.
Annual
USDFY, 2011FY, 2012FY, 2018

Revenue

(2.0m)

General and administrative expense

3.5m1.8m554.0k

R&D expense

6.4m9.0k52.0k

Operating expense total

9.9m1.8m606.0k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

2.0m

General and administrative expense

797.0k391.0k424.0k393.0k480.0k433.0k277.0k159.0k84.0k126.0k188.0k178.0k

R&D expense

1.4m1.2m556.0k403.0k667.0k912.0k749.0k386.0k322.0k507.0k601.0k427.0k

Operating expense total

2.2m1.6m980.0k796.0k1.1m1.3m1.0m545.0k406.0k633.0k789.0k605.0k
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

13.8m10.2m6.3m2.2m1.0m698.0k1.3m1.3m

Prepaid Expenses

383.0k233.0k555.0k247.0k98.0k97.0k

Current Assets

14.5m10.6m6.5m2.7m1.3m829.0k1.4m1.4m

PP&E

160.0k23.0k3.0k
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Capstone Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Capstone Therapeutics Online and Social Media Presence

Embed Graph

Capstone Therapeutics Frequently Asked Questions

  • When was Capstone Therapeutics founded?

    Capstone Therapeutics was founded in 1987.

  • Who are Capstone Therapeutics key executives?

    Capstone Therapeutics's key executives are Elwood D. Howse, Michael M. Toporek and Matthew E. Lipman.

  • How many employees does Capstone Therapeutics have?

    Capstone Therapeutics has 9 employees.

  • Who are Capstone Therapeutics competitors?

    Competitors of Capstone Therapeutics include Gotham Therapeutics, Malin and Circle Pharma.

  • Where is Capstone Therapeutics headquarters?

    Capstone Therapeutics headquarters is located at 1275 W Washington St, Tempe.

  • Where are Capstone Therapeutics offices?

    Capstone Therapeutics has an office in Tempe.

  • How many offices does Capstone Therapeutics have?

    Capstone Therapeutics has 1 office.